Company Turns Around Immature Cancer Cells To Treat Multiple Leukemias

Significant advancements in cancer research have led to highly targeted treatments for specific genetic mutations in acute myeloid leukemia (AML) and other blood cancers. One company, in particular, is making notable progress with what it anticipate will be a promising treatment for relapsed and refractory AML patients with specific mutations. As they prepare to release data from ongoing clinical trials, we are monitoring the likelihood of success. We believe this company is poised for meaningful developments with a 67.3% overall probability positive trial data will be reported.

MACE Scores are based on:

• Market Demand

• Adoption by payers and key opinion leaders (KOLs)

• Clinical progress

• Experience and capital.